Welcome to imetelstat.eu
This website collects academic, clinical and commercial information about the new drug imetelstat: the first telomerase inhibitor in clinical stage development. Imetelstat inhibits the activity of telomerase, which is an enzyme present in most types of cancer that enables tumor cells to replicate indefinitely.
The purpose of imetelstat.eu is to provide easy access to existing information about imetelstat, its basic workings, clinical potential and results from preclinical and clinical studies. Imetelstat.eu only publishes content that is publicly available and from known sources.
This website is a private initiative. It operates independently and is not funded by external parties.
Imetelstat.eu aims to be helpful for everyone interested in imetelstat, whether they are patients, relatives, scientists, investors or simply curious. People are encouraged to contact the administrator through the contact form of this site to provide suggestions for new information about imetelstat that should be uploaded to this website.